Related Experiment Video
Updated: Oct 4, 2025

Quantifying the Antifungal Activity of Peptides Against Candida albicans
Published on: January 13, 2023
Antimicrobials and resistance part II: Antifungals, antivirals, and antiparasitics
Fiorinda F Muhaj1, Saira J George1, Celine D Nguyen2
1Department of Dermatology, University of Texas McGovern Medical School at Houston, Houston, Texas; Department of Dermatology, MD Anderson Cancer Center, Houston, Texas.
Abstract:
The available antifungal armamentarium consists of only a few drug classes, many limited in their use by significant toxicities and dangerous drug interactions. Rising opportunistic multidrug-resistant pathogens in the last few decades are further limiting available treatment options in life-threatening invasive fungal diseases. Similarly, antiviral resistance, although uncommon in healthy hosts, remains a challenge in immunocompromised patients with a risk for dissemination and severe disease. As evidenced by a dry pipeline, the gravity of antifungal, antiviral, and antiparasitic resistance has yet to draw the same attention as antibacterial resistance. Resistance disproportionately affects immunocompromised and vulnerable hosts, underscoring the urgent need to develop novel therapeutics. Antifungals, antiparasitics, and antivirals of main significance will be reviewed here, along with resistance concerns and some therapeutic agents under investigation.
Insights
Antifungal, antiviral, and antiparasitic resistance is a growing threat, especially for immunocompromised patients. Novel drug development is urgently needed due to limited treatment options and dangerous drug interactions.
Area of Science:
- Infectious Diseases
- Pharmacology
- Drug Resistance
Background:
- Limited drug classes available for fungal infections, often with significant toxicities and drug interactions.
- Increasing incidence of multidrug-resistant pathogens poses a threat to treating invasive fungal diseases.
- Antiviral resistance is a challenge, particularly in immunocompromised individuals, risking disease dissemination.
Purpose of the Study:
- To review significant antifungal, antiparasitic, and antiviral agents.
- To discuss emerging resistance concerns in these therapeutic areas.
- To highlight therapeutic agents currently under investigation.
Main Methods:
- Literature review of antifungal, antiviral, and antiparasitic resistance.
- Analysis of current treatment options and their limitations.
- Examination of the drug development pipeline for novel therapeutics.
Main Results:
- Few drug classes available for antifungal treatment, with notable toxicity and interaction issues.
- Multidrug-resistant pathogens are increasingly problematic in invasive fungal infections.
- Antimicrobial resistance, particularly antifungal, antiviral, and antiparasitic, is less prioritized than antibacterial resistance despite its impact.
Conclusions:
- Urgent need for novel therapeutics to combat rising antifungal, antiviral, and antiparasitic resistance.
- Vulnerable and immunocompromised populations are disproportionately affected by resistance.
- The limited pipeline for these agents necessitates increased attention and research investment.
More Related Videos
08:58Isolation and Identification of Waterborne Antibiotic-Resistant Bacteria and Molecular Characterization of their Antibiotic Resistance Genes
Published on: March 3, 2023
06:50A Soluble Tetrazolium-Based Reduction Assay to Evaluate the Effect of Antibodies on Candida tropicalis Biofilms
Published on: September 16, 2022
Related Concept Videos
Antimicrobial Effectiveness
Combined Effects of Drugs: Synergism
Such synergistic combinations...
Biological Methods for Microbial Control
Antimicrobial Proteins
Interferons
Interferons (IFNs) are proteins produced by lymphocytes, macrophages, and fibroblasts infected with viruses. While IFNs cannot prevent viruses from entering and...
Development of Antibiotic Resistance
Gene Regulation in Microbial Communities: Quorum Sensing